powerfulpicks stock research: I track INDSWFTLABS from the levels of 40, since I had confidence in its pedigree and business plans. For half of 2009 and most part of 2010, the stock was sleeping at 60-70 level. Then the investors discovered the stock and the script ran up a lot recently; currently it is around 132. But even after the recent marathon, it is available at a P/E multiple of only 6.3 and P/BV is at 1.2...which still keeps it relatively cheap and under-valued. The company has discovered a new active pharmaceutical ingedient (API) in the class of aromatase inhibitors (anti-cancer). They named it Anastrozole and this chemical has tremendous potential with cancer on the rise in most countries of the world.
Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA. Ind-Swift Laboratories Ltd was incorporated in the year 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.
Their future looks bright with the following drug APIs in pipeline: Donepezil (Alzheimer's Disease), Fluvastatin (Cardiovascular), Nateglinide (Anti Diabetic), Naratriptan (Anti Migrane), Risedronate (Osteoporosis). Alzheimers, diabetis, migraine, heart diseases and osteoporosis are all on the rise, all over the world.
Track this script and wait for a correction to enter. It is difficult to predict a long term target for this script. 170 looks quite achievable to me. It can be much higher than that though.
No comments:
Post a Comment